Small cell ovarian carcinoma: genomic stability and responsiveness to therapeutics
暂无分享,去创建一个
D. Huntsman | Colleen A Crane | B. Vanderhyden | P. Tonin | J. Squire | S. L. Arcand | Lisa F. Gamwell | K. Gambaro | Maria Merziotis | V. Bourada | Christopher Davis
[1] H. Atkins,et al. Harnessing oncolytic virus-mediated antitumor immunity in an infected cell vaccine. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.
[2] F. Markowetz,et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups , 2012, Nature.
[3] Steven J. M. Jones,et al. Recurrent somatic DICER1 mutations in nonepithelial ovarian cancers. , 2012, The New England journal of medicine.
[4] C. Greenwood,et al. Chromosome 3 Anomalies Investigated by Genome Wide SNP Analysis of Benign, Low Malignant Potential and Low Grade Ovarian Serous Tumours , 2011, PloS one.
[5] A. Walker,et al. Prolactin increases survival and migration of ovarian cancer cells: importance of prolactin receptor type and therapeutic potential of S179D and G129R receptor antagonists. , 2011, Cancer letters.
[6] Benjamin J. Raphael,et al. Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.
[7] E. Jacobson,et al. Unexploited therapies in breast and prostate cancer: blockade of the prolactin receptor , 2010, Trends in Endocrinology & Metabolism.
[8] K. Azarow,et al. Small Cell Ovarian Carcinoma: A Rare, Aggressive Tumor Masquerading as Constipation in a Teenager With a Fatal Outcome , 2010, Journal of pediatric hematology/oncology.
[9] H. Tsuda,et al. Cumulative alterations of p27Kip1‐related cell‐cycle regulators in the development of endometriosis‐associated ovarian clear cell adenocarcinoma , 2010, Histopathology.
[10] K. Busam,et al. An Immunohistochemical Study of Cervical Neuroendocrine Carcinomas: Neoplasms That are Commonly TTF1 Positive and Which May Express CK20 and P63 , 2010, The American journal of surgical pathology.
[11] D. Kirn,et al. Navigating the clinical development landscape for oncolytic viruses and other cancer therapeutics: no shortcuts on the road to approval. , 2010, Cytokine & growth factor reviews.
[12] J. Petty,et al. Familial small cell carcinoma of the ovary , 2009, Pediatric blood & cancer.
[13] Z. Jehan,et al. Bortezomib-mediated expression of p27Kip1 through S-phase kinase protein 2 degradation in epithelial ovarian cancer , 2009, Laboratory Investigation.
[14] Steven J. M. Jones,et al. Circos: an information aesthetic for comparative genomics. , 2009, Genome research.
[15] Yonghong Xiao,et al. GOLPH3 modulates mTOR signaling and rapamycin sensitivity in cancer , 2009, Nature.
[16] K. Yao,et al. The autocrine human secreted PDZ domain-containing protein 2 (sPDZD2) induces senescence or quiescence of prostate, breast and liver cancer cells via transcriptional activation of p53. , 2008, Cancer letters.
[17] Tadao Tanaka,et al. Establishment and characterization of a human ovarian small cell carcinoma, hypercalcemic type, cell line (OS-1) secreting PTH, PTHrP and ACTH-special reference to the susceptibility of anti-cancer drugs- , 2008, Human Cell.
[18] H. Atkins,et al. Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis , 2008, Proceedings of the National Academy of Sciences.
[19] A. Mes-Masson,et al. Influence of monolayer, spheroid, and tumor growth conditions on chromosome 3 gene expression in tumorigenic epithelial ovarian cancer cell lines , 2008, BMC Medical Genomics.
[20] M. Pagano,et al. Deregulated proteolysis by the F-box proteins SKP2 and β-TrCP: tipping the scales of cancer , 2008, Nature Reviews Cancer.
[21] N. Jahchan,et al. A La-related protein modulates 7SK snRNP integrity to suppress P-TEFb-dependent transcriptional elongation and tumorigenesis. , 2008, Molecular cell.
[22] F. Mayer,et al. Results of a prospective dose-intensive regimen in 27 patients with small cell carcinoma of the ovary of the hypercalcemic type. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.
[23] D. Kirn,et al. Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963. , 2007, The Journal of clinical investigation.
[24] Anne-Marie Mes-Masson,et al. Molecular description of a 3D in vitro model for the study of epithelial ovarian cancer (EOC) , 2007, Molecular carcinogenesis.
[25] M. Nucci,et al. Biomarker‐assisted diagnosis of ovarian, cervical and pulmonary small cell carcinomas: the role of TTF‐1, WT‐1 and HPV analysis , 2007, Histopathology.
[26] J. Bell,et al. Oncolytic viruses: what's next? , 2007, Current cancer drug targets.
[27] D. Kirn,et al. From ONYX-015 to armed vaccinia viruses: the education and evolution of oncolytic virus development. , 2007, Current cancer drug targets.
[28] Jiong Wu,et al. Gene expression profile analysis of an isogenic tumour metastasis model reveals a functional role for oncogene AF1Q in breast cancer metastasis. , 2006, European journal of cancer.
[29] Robert D. Schreiber,et al. Interferons, immunity and cancer immunoediting , 2006, Nature Reviews Immunology.
[30] Yasuo Watanabe,et al. Clinical significance of Skp2 expression, alone and combined with Jab1 and p27 in epithelial ovarian tumors. , 2006, Oncology reports.
[31] J. Ledermann,et al. Small cell of the ovary, hypercalcemic type -- analysis of combined experience and recommendation for management. A GCIG study. , 2006, Gynecologic oncology.
[32] J. Bell,et al. Recent progress in the battle between oncolytic viruses and tumours , 2005, Nature Reviews Cancer.
[33] Pascal Reynier,et al. Two-step differential expression analysis reveals a new set of genes involved in thyroid oncocytic tumors. , 2005, The Journal of clinical endocrinology and metabolism.
[34] P. Clement,et al. Selected miscellaneous ovarian lesions: small cell carcinomas, mesothelial lesions, mesenchymal and mixed neoplasms, and non-neoplastic lesions , 2005, Modern Pathology.
[35] L. Cope,et al. Patterns of p53 Mutations Separate Ovarian Serous Borderline Tumors and Low- and High-grade Carcinomas and Provide Support for a New Model of Ovarian Carcinogenesis: A Mutational Analysis With Immunohistochemical Correlation , 2005, The American journal of surgical pathology.
[36] E. Oliva,et al. An Immunohistochemical Analysis of Ovarian Small Cell Carcinoma of Hypercalcemic Type , 2004, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.
[37] H. Atkins,et al. Vesicular stomatitis virus: a potential therapeutic virus for the treatment of hematologic malignancy. , 2004, Human gene therapy.
[38] T. Hudson,et al. Gene expression microarray analysis and genome databases facilitate the characterization of a chromosome 22 derived homogenously staining region , 2004, Molecular carcinogenesis.
[39] S. Yamada,et al. Stage IIIC Small Cell Carcinoma of the Ovary: Survival With Conservative Surgery and Chemotherapy , 2004, Obstetrics and gynecology.
[40] K. Shigemasa,et al. Skp2 overexpression is a prognostic factor in patients with ovarian adenocarcinoma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[41] P. Santamaria,et al. Regulation of larval hematopoiesis in Drosophila melanogaster: a role for the multi sex combs gene. , 2002, Genetics.
[42] M. Spycher,et al. Hypercalcemic-type of small cell carcinoma of the ovary: characterization of a new tumor line. , 2001, Anticancer Research.
[43] M. Rubin,et al. Activated in prostate cancer: a PDZ domain-containing protein highly expressed in human primary prostate tumors. , 2001, Cancer research.
[44] T. Fukuda,et al. Hypercalcemia due to parathyroid hormone-related protein produced by primary ovarian clear cell adenocarcinoma: case report. , 2000, Gynecologic oncology.
[45] S. Goodman,et al. PGP9.5 as a candidate tumor marker for non-small-cell lung cancer. , 1999, The American journal of pathology.
[46] J. Foekens,et al. Genetic alterations in ovarian borderline tumours and ovarian carcinomas. , 1999, European journal of obstetrics, gynecology, and reproductive biology.
[47] R. McCoy,et al. UTERINE AND OVARIAN CONSERVATION IN ADVANCED SMALL CELL CARCINOMA OF THE OVARY , 1998, Obstetrics and gynecology.
[48] F. Cappuccini,et al. Advanced-stage small cell carcinoma of the ovary in pregnancy: long-term survival after surgical debulking and multiagent chemotherapy. , 1997, Gynecologic oncology.
[49] A. Villanueva,et al. K‐ras mutations in mucinous ovarian tumors , 1997, Cancer.
[50] Thomas Ried,et al. Hidden chromosome abnormalities in haematological malignancies detected by multicolour spectral karyotyping , 1997, Nature Genetics.
[51] Y. Tachimori,et al. Circulating parathyroid hormone-related protein (109-141) in malignancy-associated hypercalcemia. , 1996, Japanese journal of clinical oncology.
[52] A. Cohen,et al. A novel gene, AF1q, fused to MLL in t(1;11) (q21;q23), is specifically expressed in leukemic and immature hematopoietic cells. , 1995, Blood.
[53] E. Oliva,et al. Small Cell Carcinoma of the Ovary, Hypercalcemic Type: A Clinicopathological Analysis of 150 Cases , 1994, The American journal of surgical pathology.
[54] E. Chen,et al. A parathyroid hormone-related protein implicated in malignant hypercalcemia: cloning and expression. , 1987, Science.
[55] S. Krane,et al. Differential cyclic AMP responses to calcitonin among human ovarian carcinoma cell lines: A calcitonin‐responsive line derived from a rare tumor type , 1986, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[56] M. Winker,et al. Radiation survival parameters of antineoplastic drug-sensitive and -resistant human ovarian cancer cell lines and their modification by buthionine sulfoximine. , 1985, Cancer research.
[57] B. Vanderhyden,et al. Conditional inactivation of Brca1 in the mouse ovarian surface epithelium results in an increase in preneoplastic changes. , 2007, Experimental cell research.
[58] A. C. Webb,et al. Identification of a cDNA encoding a parathyroid hormone-like peptide from a human tumor associated with humoral hypercalcemia of malignancy. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[59] R. Scully,et al. Small cell carcinoma of the ovary with hypercalcemia: A report of eleven cases , 1982, Cancer.